12:00 AM
Jan 24, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RTX resiniferatoxin: Began Phase II study

Afferon Corp., Wayne, Penn.
Product: RTX resiniferatoxin
Business: Urological, Neurological
Therapeutic category: Neurotransmission
Target: Peripheral sensory neurons
Description: Neuronal desensitizing agent...

Read the full 81 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >